Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus
Abstract We hypothesize that serum irisin can have additional discriminative potency for heart failure (HF) in individuals with type 2 diabetes mellitus (T2DM). The study group comprised 226 consecutive T2DM patients (153 patients with any HF phenotypes and 30 patients without HF) aged 41 to 65 year...
Main Authors: | Alexander A. Berezin, Ivan M. Fushtey, Sergii V. Pavlov, Alexander E. Berezin |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2022-11-01
|
Series: | Molecular Biomedicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43556-022-00096-x |
Similar Items
-
Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus
by: Alexander A. Berezin, et al.
Published: (2022-05-01) -
Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
by: Alexander A. Berezin, et al.
Published: (2023-03-01) -
Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
by: Alexander A. Berezin, et al.
Published: (2022-09-01) -
The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
by: Alexander A. Berezin, et al.
Published: (2022-07-01) -
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure
by: Alexander A. Berezin, et al.
Published: (2023-02-01)